Drug Stocks In Red Zone: Zogenix (NASDAQ:ZGNX), TherapeuticsMD Inc. (NYSEMKT:TXMD), Intercept Pharmaceuticals (NASDAQ:ICPT), Retrophin Inc. (NASDAQ:RTRX)

Zogenix, Inc. (NASDAQ:ZGNX) announced that it has entered a definitive agreement to sell its SUMAVEL DosePro Needle-free Delivery System (sumatriptan injection) migraine therapy business to Endo International plc (Nasdaq: ENDP) for $85 million in cash and milestone payments of up to $20 million. Zogenix, Inc. (NASDAQ:ZGNX) stock opened today at $3.05 and is currently trading at $2.88. The stock showed a positive weekly performance of 20.09%.

TherapeuticsMD, Inc. (NYSEMKT:TXMD), a women’s healthcare company (“TherapeuticsMD” or the “Company”), announced that it received approval to begin screening and enrolling subjects at its fiftieth site, the University of Florida College of Medicine, in the Company’s REPLENISH Trial, a phase 3, double-blind, placebo-controlled clinical trial designed to measure the safety and effectiveness of TX 12-001HR, the Company’s bio-identical combination 17beta-estradiol and progesterone drug candidate, in treating the symptoms of menopause. TherapeuticsMD Inc. (NYSEMKT:TXMD) stock opened at $4.92, in current trading session and currently is at $4.50, by losing -5.66%. The 52 week range of $2.03 – $9.01. Company’s market capitalization is 652.85 million.

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) Net operating cash flow has significantly decreased to -$10.43 million or 142.89% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm’s growth rate is much lower. Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) stock is currently trading at $262.37. The EPS of the stock is -3.70. Company’s market capitalization is 5.28 billion.

Retrophin, Inc. (NASDAQ:RTRX) announced completion of its previously-announced acquisition of the Manchester Pharmaceuticals LLC for $62.5M, including its upfront-payment of $29.5M, plus the other payments that are based on the product sales. Retrophin Inc. (NASDAQ:RTRX) stock opened the session at $13.89, and now is at $12.88. The 52 week range of the Retrophin Inc. (NASDAQ:RTRX) stock remained $4.50 – $24.25 and the day range was $12.80 – $13.94.